Serum prolidase I activity and some bone metabolic markers in patients with breast cancer: in relation to menopausal status.

Autor: Kir ZO; Department of Biochemistry, Istanbul Faculty of Medicine, Istanbull University, Capa, 34093 Istanbul, Turkey., Oner P, Iyidoğan YO, Türkmen S, Koçak H, Koşer M, Küçücük SO
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2003 Jun; Vol. 36 (4), pp. 289-94.
DOI: 10.1016/s0009-9120(03)00028-6
Abstrakt: Objectives: The purpose of this study was to investigate the diagnostic value of some osteoblastic/osteoclastic biochemical markers and serum prolidase I activity in breast cancer (BC).
Design and Methods: Serum bone gla protein (BGP), prolidase I activity, urinary deoxypyridinoline (Dpy) and calcium excretions were measured, in metastatic and nonmetastatic BC patients, and in 52 healthy women.
Results: In patients with metastases, bone turnover markers were found to be significantly higher than those in the control group and in patients without metastases. Serum prolidase activity in patients with and without metastases was also significantly higher than those in the control group, but there was no difference between the two patient groups.
Conclusions: Bone turnover has been suggested to be accelerated in BC patients with the more pronounced osteolytic activation, especially in metastatic state. Serum prolidase in premenopausal period appears to be valuable in discriminating cancer patients from controls. BGP and to a lesser degree of Dpy, may be useful markers for predicting the metastatic bone involvement, as well as for the more cost effective management of BC patients and monitoring the effects of antiresorptive therapy of malignant osteolysis before any metastasis could be detected by other invasive techniques.
Databáze: MEDLINE
Externí odkaz: